Impact of extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) rectal carriage in cancer patients admitted to the intensive care unit.

Nahéma Issa, Maider Coppry, Eva Ripoche, Olivier Guisset, Gaelle Mourissoux, Emile Bessede, Fabrice Camou

Infectious diseases now 2022 Mar

filter terms:

Little data is available on extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) rectal colonization in cancer patients admitted to the intensive care unit (ICU). We aimed to describe the epidemiology of ESBL-E in cancer patients hospitalized in the ICU compared with non-cancer patients. ESBL-E colonization was detected in 6.6% of 1,013 cancer patients and 6.4% of 1625 non-cancer patients. At admission, among the 172 colonized patients: 48/67 cancer patients and 78/105 non-cancer patients developed an infection, documented with an ESBL-E for 21% and 24% of them, respectively. The in-hospital mortality rate among colonized patients was 33% in cancer patients and 12% in non-cancer patients. In cancer patients, ESBL-E infections are rare but systematic rectal screening identifies high-risk population and guides empirical antibiotic therapy. It also contributes to being aware of the ICU microbiological ecology. Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Citation

Nahéma Issa, Maider Coppry, Eva Ripoche, Olivier Guisset, Gaelle Mourissoux, Emile Bessede, Fabrice Camou. Impact of extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) rectal carriage in cancer patients admitted to the intensive care unit. Infectious diseases now. 2022 Mar;52(2):104-106